- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
High level delegation from USFDA visits Divi's Labs Choutuppal facility
Hyderabad: Divi's Laboratories Limited has announced that a high-level delegation from the U.S. Food and Drug Administration (USFDA), including Commissioner Dr. Robert M. Califf, India Country Director Dr. Sarah McMullen, and other officials, visited the company's manufacturing facility in Choutuppal, Telangana, India.
The delegation's visit covered a wide range of topics, reflecting the dynamic landscape of the Active Pharmaceutical Ingredient (API) industry, the integration of new technologies, sustainable practices in chemistry, raising manufacturing standards, and ensuring the availability of APIs.
"The company showcased its large-scale world-class production facilities, advanced automated manufacturing capabilities, commitment to innovation, and its crucial role in investing in new technologies to ensure a consistent supply of high-quality APIs," Divi's Labs stated.
“We are proud to participate in this important visit to share our role as a reliable API manufacturer that can deliver large quantities in a relatively short time,” stated Dr. Kiran S Divi, CEO of Divi's Laboratories Limited. “We look forward to continuing to engage and be a part of addressing critical issues that affect the worldwide pharmaceutical industry.”
Divi's Laboratories Limited is a pharmaceutical manufacturing company. The company has global presence in supplying APIs to more than 100 countries.Itcurrently operates two manufacturing locations that are compliant with global regulatory standards and capable of producing annual requirements ranging from 10’s of kilos to 1000’s of tons.
Read also: Emcure Pharma aims to raise USD 400- USD 500 million from IPO planned for next year
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751